Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) announced today that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This marks the second approved indication for Zytorvi® in India, expanding its use beyond its initial approval in nasopharyngeal carcinoma (NPC).

Expanding Access to Immunotherapy

Through this approval, Dr. Reddy’s Laboratories Ltd. aims to expand access to first-line immunotherapy for appropriate patients with advanced ESCC in India. The approval is supported by the results from the Phase 3 JUPITER-06 trial, which demonstrated a 42% reduction in the risk of disease or death compared with chemotherapy alone.

Significant Market Opportunity

In 2024, esophageal cancer was the fourth leading cause of cancer-related death in India, accounting for approximately 8.1% of all cancer deaths. ESCC, the predominant subtype, accounts for approximately 80% of all esophageal cancer cases in India. With this approval, Dr. Reddy’s Laboratories Ltd. is taking a significant step in addressing this critical need.

M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said: “Following the approval of Zytorvi® in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced esophageal squamous cell carcinoma. It gives physicians an additional first-line treatment option for appropriate patients. As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.

Sun Pharmaceutical Industries Limited (SUNPHARMA) announced today that UNLOXCYT® (cosibelimab-ipdl) has received a Category 2A recommended option in the updated National Comprehensive Cancer Network® (NCCN®) guidelines for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients who are not candidates for curative surgery or curative radiation. This marks a significant milestone, reflecting the growing body of clinical evidence supporting UNLOXCYT.

Clinical Evidence and Patient Benefits

The evidence submitted to NCCN was based on the pivotal registration study, in which 55% of patients achieved an objective response, including 26% who achieved a complete response. Responses were durable with a median follow-up of 24.1 months and a median duration of response not yet reached. Importantly, fewer than 1% of patients experienced high-grade immune-mediated adverse reactions, which is crucial for this patient population.

Impact on Patient Access

The NCCN Guidelines play a vital role in helping physicians evaluate appropriate treatment options for patients across different disease settings. This designation ensures that appropriate patients can receive this treatment without unnecessary access barriers, offering a therapy that provides durable responses with a low rate of high-grade adverse reactions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun falls 9.0% over three months and has not found a floor yet. The PEG reaches 3.29. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 38% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.0% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.

Wanbury Limited (WANBURY) has recently received significant recognition for its safety and employee practices. On October 19, 2026, the company announced that its Tanuku and Patalganga facilities have been awarded for their outstanding achievements. Notably, the Patalganga facility in Maharashtra received the “Certificate of Excellence” from the National Safety Council for safety performance for the third consecutive year. Meanwhile, the Tanuku facility in Andhra Pradesh was named the “Best Employer” by the State Government, recognizing its exemplary employee practices and workplace culture.

Recognition for Safety

The Patalganga facility’s continuous commitment to maintaining high safety standards has been acknowledged by receiving the “Certificate of Excellence” from the National Safety Council for three years in a row. This recognition underscores the facility’s dedication to ensuring a safe working environment for its employees and compliance with stringent safety regulations.

Awards for Employee Practices

The Tanuku facility’s award as the “Best Employer” highlights its efforts in fostering a rewarding and compliant workplace. The recognition emphasizes the company’s commitment to employee welfare and its efforts to create a positive workplace culture. These accolades reflect Wanbury’s ongoing efforts to uphold high environment, health, and safety (EHS) standards while adhering to Good Manufacturing Practice (GMP) norms.

Management Commentary

“Our people and their safety are at the heart of everything we do,” said Mr. Mohan Rayana, Director of Wanbury Limited. “These awards for our Tanuku and Patalganga teams recognize their dedication to a safe, compliant, and rewarding workplace. We will keep raising the bar on employee welfare and safety across all our sites.” This statement from Mr. Rayana highlights the company’s dedication to its workforce and its continuous efforts to improve safety and employee practices.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Wanbury Limited

Wanbury Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Wanbury drops 42.1% over three months and trades near its 52-week lows. Thin margins at 8.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock sits at 16% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Wanbury Limited.